Genesys Venture

Profound Medical Corp. is a medical technology company based in Mississauga, Canada, specializing in the development of innovative, incision-free therapeutic systems for the image-guided ablation of diseased tissue. The company’s flagship product, the TULSA-PRO system, integrates real-time magnetic resonance imaging with robotically driven thermal ultrasound to precisely ablate prostate tissue. Additionally, Profound Medical offers the Sonalleve platform, which is designed for treating uterine fibroids and managing palliative pain associated with bone metastases. By leveraging existing MRI infrastructure, the company aims to provide customizable and non-invasive treatment options that address the unmet needs of patients and clinicians. Profound Medical is committed to enhancing the standard of care through its advanced technologies and has established a co-development agreement with GE Healthcare to broaden access to its TULSA-PRO system.

Profound Medical Corp. is a medical technology company based in Mississauga, Canada, specializing in the development of innovative, incision-free therapeutic systems for the image-guided ablation of diseased tissue. The company’s flagship product, the TULSA-PRO system, integrates real-time magnetic resonance imaging with robotically driven thermal ultrasound to precisely ablate prostate tissue. Additionally, Profound Medical offers the Sonalleve platform, which is designed for treating uterine fibroids and managing palliative pain associated with bone metastases. By leveraging existing MRI infrastructure, the company aims to provide customizable and non-invasive treatment options that address the unmet needs of patients and clinicians. Profound Medical is committed to enhancing the standard of care through its advanced technologies and has established a co-development agreement with GE Healthcare to broaden access to its TULSA-PRO system.

GVI Clinical Development Solutions Inc. is a contract research organization (CRO) based in Winnipeg, Canada, that provides comprehensive clinical development support and strategic consulting services to biotechnology, pharmaceutical, diagnostic, and medical device companies. The firm specializes in medical needs assessments, clinical development planning, regulatory strategy, and business planning. GVI offers a range of clinical trial management services, including protocol development, investigator selection, vendor management, and resource planning. The company also executes clinical trials through management and monitoring, data collection, training for sponsor and investigational staff, and pharmacovigilance. Additionally, GVI provides quality assurance and training services, which encompass clinical trial audits, the development of standard operating procedures, and training for both sponsor and clinical trial site personnel. By focusing on small to medium-sized firms, GVI aims to deliver tailored and effective solutions in the clinical development landscape.

Kane Biotech is a Winnipeg-based biotechnology company focused on researching, developing and commercializing technologies that prevent and remove microbial biofilms in medical, veterinary and industrial settings. It maintains a portfolio of antibiofilm and anti-infective technologies with applications across wound care, medical devices, oral care, animal health and food processing, including DispersinB and ALEDEX. The company operates through animal health and human health segments and pursues international markets, leveraging its intellectual property and collaborations with research institutions to bring biofilm prevention and removal solutions to market. Founded in 2001, Kane Biotech translates biofilm science into products that reduce infections and contamination across industries.

DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company based in Minneapolis, Minnesota, dedicated to developing innovative treatments for kidney and neurological diseases. The company's lead drug candidate, DM199, is a recombinant human tissue kallikrein-1 protein. It has completed Phase Ib clinical trials for treating moderate to severe chronic kidney disease linked to Type I or Type II diabetes and is undergoing Phase II trials for acute ischemic stroke. DM199 has been administered to nearly 100 patients, demonstrating a safe and well-tolerated profile. Additionally, DiaMedica is developing DMDx, a diagnostic tool to measure human tissue kallikrein-1 levels. The company has a collaboration agreement with Ahon Pharmaceutical Co Ltd. to further develop and commercialize DM199 for acute ischemic stroke. DiaMedica Therapeutics was founded in 2000 and was previously known as DiaMedica Inc. before rebranding in December 2016.

Canam Bioresearch Inc., established in 2000 and headquartered in Winnipeg, Canada, is a pharmaceutical contract research organization specializing in pre-clinical discovery services. The company offers a range of services including synthetic organic chemistry and medicinal chemistry research, analytical chemistry and bioanalysis (such as HPLC-UV analysis, LC-MS analysis, plasma/blood/tissue distribution analysis, chemical purity determination, certificates of analysis, GC/MS EI analysis), process monitoring, stability and solubility determinations, and custom chemical synthesis and characterization. Canam serves pharmaceutical companies and academic institutions, ensuring confidentiality and intellectual property protection throughout its services.